✉news HealthMedicine first seen 1 d ago, last 1 d ago, peak #37
AnnJi Advances AJ201 Into Phase 3 Trial for Kennedy's Disease
Original: AnnJi Advances AJ201 Into Phase 3 Trial for Kennedy’s Disease
Biotech company AnnJi is moving its drug candidate AJ201 into a Phase 3 clinical trial for Kennedy's disease, a rare genetic neuromuscular disorder also known as spinal and bulbar muscular atrophy. The advance marks a significant step in developing a treatment for a condition that currently has no approved cure. Details on trial design and timing have not been released.
Why now: A rare disease with no approved treatment is one step closer to a potential therapy, drawing attention from patients and the medical community.
Evidence
- AnnJi Advances AJ201 Into Phase 3 Trial for Kennedy’s Disease · The Clinical Trial Vanguard
API: https://socialmediatrends-api.osmike.com/v1/trends/1081133